pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Aug 4·1 min read
save

Experts debate extra regulation for low-risk digital wellness devices

Aug 4, 2026·read at raps ↗RegulatoryNeutral

Two recent papers published in JAMA have highlighted concerns about low-risk digital health technologies that consumers use.

Experts say that even though these tools are considered low-risk, they may warrant tighter regulatory oversight to protect users.

The debate focuses on finding a balance between encouraging innovation and ensuring safety, with no specific regulatory actions announced yet.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Experts question need for more regulatory scrutiny of digital wellness devices”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoThis Week at FDA: Overton nomination hearing, FDA’s hiring challenges, and moreraps
  • 2d agoRecon: Senate hearing set for FDA nominee; Novo partners with Anthropic for AI drug developmentraps
  • 2d agoEuro Roundup: MHRA commission makes recommendations on AI regulatory framework in the UKraps
  • 2d agoConvergence: Califf says regulations ‘need an update,’ sees AI assistants in regulatory futureraps
  • 2d agoConvergence: EU officials tout pending pharmaceutical reformsraps